Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (1): 126-129.doi: 10.3969/j.issn.1673-8225.2011. 01.028

Previous Articles     Next Articles

How long will the disease-specific induced pluripotent stem cells be applied in the clinical treatment of neurodegenerative diseases  

Luo Hu1, Liu Yu-kai1, Li Ze-gui2   

  1. 1The Seventeen Student Group, Third Military Medical University of Chinese PLA, Chongqing  400038, China
    2Department of Pharmacognosy, Pharmacy College, Third Military Medical University of Chinese PLA, Chongqing  400038, China
  • Received:2010-09-21 Revised:2010-10-26 Online:2011-01-01 Published:2011-01-01
  • Contact: Li Ze-gui, Doctor, Professor, Department of Pharmacognosy, Pharmacy College, Third Military Medical University of Chinese PLA, Chongqing 400038, China lizegui@tmmu.edu.cn
  • About author:Luo Hu, The Seventeen Student Group, Third Military Medical University of Chinese PLA, Chongqing 400038, China luohucy@163.com
  • Supported by:

    the Innovation Foundation of Third Military Medical University of Chinese PLA, No. 2007XG42

PDF

486

Abstract:

BACKGROUND: Both the medical treatments and the surgery can only relieve the symptoms but not prevent the progress of neurodegenerative diseases. Cell replacement therapy proceeds fast but its ethical problem and immune rejection also should be in consideration. However, the production of induced pluripotent stem cells provides us a new way to resolve these problems.
OBJECTIVE: To review the basic situations and current treatment of neurodegenerative diseases and the possibility of the induced pluripotent stem (iPS) cells be used in regenerative medicine as a new cell resource.
METHODS: The PubMed database (http://www.ncbi.nlm.nih.gov/PubMed) and Wanfang database (http://www.wanfangdata.com.cn) were retrieved for articles published from 1995 to 2010 by computer. The English key words were “induced pluripotent stem cell, PD, ALS, SMA, degenerative disease”. The Chinese key words were “stem cells, Parkinson’s disease”. Totally 374 papers were primarily gotten. Finally, 29 papers were selected according to the inclusion criteria.
RERULTS AND CONCLUSION: Patient-specific iPS cells can obtain the same genotype which is beneficial to the elucidation of the molecular mechanism of these diseases. These cells also posses the similar multi-directional differentiation ability as embryonic stem cells, which could be induced to dopamine neurons and relieve the clinical symptoms of Parkinson’s disease in animal model in vitro. The iPS cells have broad prospect in the treatment of neurodegenerative diseases.

CLC Number: